Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.
Nectero Medical has raised $96.0M in total funding. The most recent round was Series D. The last funding was announced in April 2024.
Nectero Medical's investors include Alumni Ventures, Norwest, Boston Scientific, BioStar Capital, Aphelion Capital.
Nectero Medical is headquartered in Tempe, United States.
Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.
Nectero Medical is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nectero Medical — Funding & Investors." VCBacked, April 11, 2024, https://www.vcbacked.co/company/nectero-medical. Accessed July 20, 2026.
VCBacked. (2024). Nectero Medical — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/nectero-medical
{{cite web |title=Nectero Medical — Funding & Investors |url=https://www.vcbacked.co/company/nectero-medical |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated